DiscGenics to Present at 2018 Cell & Gene Meeting on the Mesa
SALT LAKE CITY, Sept. 26, 2018 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Flagg Flanagan, Chairman and CEO, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, on Wednesday, October 3, 2018 at 4:15pm PDT.
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is the largest partnering meeting organized specifically for the cell and gene therapy sector. The three-day meeting will be held October 3-5 at the Estancia La Jolla Hotel & Spa in La Jolla, CA, and will feature three distinct parts: the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.
DiscGenics is a privately held, clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics' first product candidate, an injectable disc cell therapy, or IDCT, is a homologous, allogeneic cell therapy that utilizes proprietary Discogenic Cells to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease.